Orforglipron ( LY3502970 ), a novel, oral non‐peptide glucagon‐like peptide‐1 receptor agonist: A Phase 1a, blinded, placebo‐controlled, randomized, single‐ and multiple‐ascending‐dose study in healthy participants
Diabetes, Obesity and Metabolism · 2023-09 · 25 (9) · 2634-2641
DOI: 10.1111/dom.15184 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 21.06.2023. Verfasst von Edward Pratt und 7 weiteren Autor:innen. Beteiligte Einrichtung: Lilly Centre for Clinical Pharmacology Pte Ltd, Singapore. Hauptthemen laut MEDLINE: Hypoglycemic Agents, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 61-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Eli Lilly and Company.
Abstract (Originalsprache)
Aim To evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple doses of orforglipron (LY3502970), an oral, non‐peptide glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) in healthy participants. Materials and Methods This was a double‐blind, placebo‐controlled, Phase 1 study. Overtly healthy adults aged 18 to 65 years with body mass index of 20 to 40 kg/m 2 and glycated haemoglobin concentration of 47.5 mmol/mol (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Lilly Centre for Clinical Pharmacology Pte Ltd, Singapore.
- Eli Lilly and Company, Indianapolis, Indiana, USA.
ORCID-Profile: Edward Pratt, Axel Haupt, Tamer Coskun
Förderung
- Eli Lilly and Company
Zitieren
APA
Pratt, E., Ma, X., Liu, R., Robins, D., Haupt, A., Coskun, T., Sloop, K. W., & Benson, C. (2023). Orforglipron ( LY3502970 ), a novel, oral non‐peptide glucagon‐like peptide‐1 receptor agonist: A Phase 1a, blinded, placebo‐controlled, randomized, single‐ and multiple‐ascending‐dose study in healthy participants. Diabetes, Obesity and Metabolism, 25(9), 2634-2641. https://doi.org/10.1111/dom.15184
Vancouver
Pratt E, Ma X, Liu R, Robins D, Haupt A, Coskun T, et al. Orforglipron ( LY3502970 ), a novel, oral non‐peptide glucagon‐like peptide‐1 receptor agonist: A Phase 1a, blinded, placebo‐controlled, randomized, single‐ and multiple‐ascending‐dose study in healthy participants. Diabetes, Obesity and Metabolism. 2023;25(9):2634-2641. doi:10.1111/dom.15184
BibTeX
@article{Pratt2023,
author = {Pratt, Edward and Ma, Xiaosu and Liu, Rong and Robins, Deborah and Haupt, Axel and Coskun, Tamer and Sloop, Kyle W and Benson, Charles},
title = {Orforglipron ( LY3502970 ), a novel, oral non‐peptide glucagon‐like peptide‐1 receptor agonist: A Phase 1a, blinded, placebo‐controlled, randomized, single‐ and multiple‐ascending‐dose study in healthy participants},
journal = {Diabetes, Obesity and Metabolism},
year = {2023},
volume = {25},
number = {9},
pages = {2634--2641},
doi = {10.1111/dom.15184}
}
EUVIMED